VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$28.92+1.04 (+3.73%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 84.9% | -50.7% | |
| Return on assets | – | – | -43.1% | |
| Current ratio | – | 22.55 | 13.64 | |
| Interest coverage | – | -314.7× | -41.9× | |
| Diluted shares | – | 0M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vera Therapeutics generated $559.27M from operations and spent $1.74M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$559.27M
Used
$1.74M
Capital expenditure$1.73M99%Dividends$00%Share buybacks$13.00K1%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$299.62M
- Cash generatingOperating cash flow above zero-$241.10M
- Return on assets improvedROA up on the prior year-86.7% → -45.7%
- Earnings backed by cashOperating cash flow above net income-$241.10M vs -$299.62M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose25.67 → 13.64
- No dilutionShare count did not rise55M → 64M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –